Boehringer Ingelheim has moved one of its top pipeline prospects – oral phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 – into late-stage clinical testing for idiopathic pulmonary fibrosis ...
Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback